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Abstract
Background: Adiposity, assessed as elevated body mass index (BMI), is associated with increased risk of ischemic heart
disease (IHD); however, whether this is causal is unknown. We tested the hypothesis that positive observational associations
between BMI and IHD are causal.
Methods and Findings: In 75,627 individuals taken from two population-based and one case-control study in Copenhagen,
we measured BMI, ascertained 11,056 IHD events, and genotyped FTO(rs9939609), MC4R(rs17782313), and
TMEM18(rs6548238). Using genotypes as a combined allele score in instrumental variable analyses, the causal odds ratio
(OR) between BMI and IHD was estimated and compared with observational estimates. The allele score-BMI and the allele
score-IHD associations used to estimate the causal OR were also calculated individually. In observational analyses the OR for
IHD was 1.26 (95% CI 1.19–1.34) for every 4 kg/m
2 increase in BMI. A one-unit allele score increase associated with a 0.28 kg/
m
2 (95 CI% 0.20–0.36) increase in BMI and an OR for IHD of 1.03 (95% CI 1.01–1.05) (corresponding to an average 1.68 kg/m
2
BMI increase and 18% increase in the odds of IHD for those carrying all six BMI increasing alleles). In instrumental variable
analysis using the same allele score the causal IHD OR for a 4 kg/m
2 increase in BMI was 1.52 (95% CI 1.12–2.05).
Conclusions: For every 4 kg/m
2 increase in BMI, observational estimates suggested a 26% increase in odds for IHD while
causal estimates suggested a 52% increase. These data add evidence to support a causal link between increased BMI and
IHD risk, though the mechanism may ultimately be through intermediate factors like hypertension, dyslipidemia, and type 2
diabetes. This work has important policy implications for public health, given the continuous nature of the BMI-IHD
association and the modifiable nature of BMI. This analysis demonstrates the value of observational studies and their ability
to provide unbiased results through inclusion of genetic data avoiding confounding, reverse causation, and bias.
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Causal Effects: BMI and Ischemic Heart Disease
PLoS Medicine | www.plosmedicine.org 2 May 2012 | Volume 9 | Issue 5 | e1001212Introduction
Observational examination of the prospective association
between body mass index (BMI) and ischemic heart disease
(IHD) has been undertaken in a range of populations [1–3] and
has consistently shown a positive relationship between BMI and
the risk of IHD and other vascular endpoints [4–9]; however,
causality in this relationship has not been convincingly demon-
strated.
Observational association of BMI with IHD is impaired by
confounding [10], reverse causation [11,12], and bias [12],
making it difficult to infer causality. An alternative approach free
of confounding, reverse causation, and bias is that of Mendelian
randomisation [13]. Mendelian randomisation uses analyses
analogous to those in a randomized trial, but where randomization
to risk-factor–related genotypes takes place at conception. In
the case of IHD, genotypes with the largest known effects on
BMI [14], (FTO[rs9939609], MC4R[rs17782313], and TMEM18
[rs6548238]), can be used [15] for the reassessment of BMI as a
causal risk factor for disease risk.
Genetic variation at the fat mass and obesity related locus (FTO)
is thought to have a role in the hypothalamic regulation of appetite
and food intake or metabolic rate [16–21] and has already been
used to interrogate the relationship between BMI and acute
coronary syndrome, lipid profile in myocardial infarction patients,
and mortality [22–24]. Furthermore, variation at the same locus
has been associated with atherogenic lipid profile and myocardial
infarction risk in a manner that suggests an important role for
BMI, but that remains unclear [23]. Although, the mechanism of
the association between common variation at MC4R and
TMEM18 loci and adiposity is currently unclear, these genotypes
may still be used to provide evidence of the role of BMI in IHD
risk. Indeed, the use of multiple independent genetic instruments
for a single risk factor in the undertaking of Mendelian randomisa-
tion experiments is recognised as a favourable approach [25].
The aim here was to test the hypothesis that known positive
observational relationships between BMI and IHD are causal in
two well-sized general population studies (the Copenhagen
General Population Study [CGPS]; n=54,613 [3,780 patients
with IHD] and the Copenhagen City Heart Study [CCHS];
n=10,474 [2,006 patients with IHD]) and in a large collection of
IHD patients with matched controls (the Copenhagen Ischaemic
Heart Disease Study [CIHDS]; n=10,540 [5,270 patients with
IHD]). Analyses were designed to use an allele score as an
unconfounded marker of BMI, and to take advantage of the use
of loci FTO(rs9939609), MC4R(rs17782313), and TMEM18
(rs6548238) as multiple independent instruments for BMI in
efforts to address the potential complicating issue of biological
confounding (or pleiotropy). In these analyses, allele score is used
as an instrument for assessing the causal relationship between BMI
increase and increased IHD risk, which is then directly compared
with the observational BMI-IHD association. To evaluate ‘‘raw’’
data, we also show the different parts of the analyses separately,
that is, first the BMI-IHD association, second the allele score-BMI
association, and third the allele score-IHD association.
Methods
Participants
All participants were white and of Danish descent; this
information is available through the national Danish Central
Person Registry. No participants appeared in more than one of the
three studies. The studies were approved by Danish ethical
committees and Herlev Hospital.
D
a
t
a
a
r
e
f
r
o
m
s
t
u
d
y
e
n
r
o
l
m
e
n
t
i
n
2
0
0
3
–
2
0
0
9
i
n
t
h
e
C
G
P
S
,
f
r
o
m
t
h
e
1
9
9
1
–
1
9
9
4
o
r
2
0
0
1
–
2
0
0
3
e
x
a
m
i
n
a
t
i
o
n
s
o
f
t
h
e
C
C
H
S
w
h
e
n
D
N
A
w
a
s
c
o
l
l
e
c
t
e
d
,
a
n
d
f
r
o
m
s
t
u
d
y
e
n
r
o
l
m
e
n
t
i
n
1
9
9
1
–
2
0
0
9
i
n
t
h
e
C
I
D
H
S
.
V
a
l
u
e
s
a
r
e
m
e
d
i
a
n
a
n
d
i
n
t
e
r
q
u
a
r
t
i
l
e
r
a
n
g
e
o
r
n
u
m
b
e
r
o
f
p
a
r
t
i
c
i
p
a
n
t
s
a
n
d
p
e
r
c
e
n
t
a
g
e
s
.
D
r
i
n
k
i
n
g
a
l
c
o
h
o
l
r
e
p
r
e
s
e
n
t
e
d
b
y
,
1
4
/
2
1
;
$
1
4
/
2
1
u
n
i
t
s
p
e
r
w
e
e
k
f
o
r
w
o
m
e
n
/
m
e
n
a
t
t
h
e
t
i
m
e
o
f
e
x
a
m
i
n
a
t
i
o
n
.
E
v
e
n
t
t
i
m
e
i
s
t
h
e
a
b
s
o
l
u
t
e
v
a
l
u
e
o
f
t
h
e
d
i
f
f
e
r
e
n
c
e
b
e
t
w
e
e
n
a
g
e
a
t
I
H
D
e
v
e
n
t
a
n
d
a
g
e
a
t
m
e
a
s
u
r
e
m
e
n
t
o
f
B
M
I
(
y
)
.
S
B
P
a
n
d
D
B
P
a
d
j
u
s
t
e
d
b
y
a
d
d
i
n
g
1
0
a
n
d
5
m
m
H
g
t
o
e
a
c
h
,
r
e
s
p
e
c
t
i
v
e
l
y
,
i
f
p
a
t
i
e
n
t
o
n
A
H
m
e
d
i
c
a
t
i
o
n
.
T
o
c
o
n
v
e
r
t
g
l
u
c
o
s
e
v
a
l
u
e
s
i
n
m
m
o
l
/
l
t
o
m
g
/
d
l
,
m
u
l
t
i
p
l
y
b
y
1
8
.
T
o
c
o
n
v
e
r
t
L
D
L
a
n
d
H
D
L
c
h
o
l
e
s
t
e
r
o
l
v
a
l
u
e
s
i
n
m
m
o
l
/
l
t
o
m
g
/
d
l
,
m
u
l
t
i
p
l
y
b
y
3
8
.
6
.
T
o
c
o
n
v
e
r
t
t
r
i
g
l
y
c
e
r
i
d
e
v
a
l
u
e
s
i
n
m
m
o
l
/
l
t
o
m
g
/
d
l
,
m
u
l
t
i
p
l
y
b
y
8
8
.
I
n
C
I
H
D
S
,
e
d
u
c
a
t
i
o
n
a
n
d
i
n
c
o
m
e
a
r
e
o
n
l
y
a
v
a
i
l
a
b
l
e
i
n
c
o
n
t
r
o
l
s
.
a
,
1
0
y
o
f
s
c
h
o
o
l
i
n
g
.
b
$
1
0
t
o
,
1
3
y
o
f
s
c
h
o
o
l
i
n
g
.
c
$
1
3
y
o
f
s
c
h
o
o
l
i
n
g
.
d
,
1
0
0
,
0
0
0
D
K
K
a
n
n
u
a
l
i
n
c
o
m
e
.
e
1
0
0
,
0
0
0
D
K
K
–
4
0
0
,
0
0
0
D
K
K
a
n
n
u
a
l
i
n
c
o
m
e
.
f
4
0
0
,
0
0
0
–
6
0
0
,
0
0
0
D
K
K
a
n
n
u
a
l
i
n
c
o
m
e
.
g
.
6
0
0
,
0
0
0
D
K
K
a
n
n
u
a
l
i
n
c
o
m
e
.
A
H
,
a
n
t
i
h
y
p
e
r
t
e
n
s
i
v
e
;
D
B
P
,
d
i
a
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
;
H
D
L
,
h
i
g
h
d
e
n
s
i
t
y
l
i
p
o
p
r
o
t
e
i
n
;
L
D
L
,
l
o
w
d
e
n
s
i
t
y
l
i
p
o
p
r
o
t
e
i
n
;
S
B
P
,
s
y
s
t
o
l
i
c
b
l
o
o
d
p
r
e
s
s
u
r
e
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
m
e
d
.
1
0
0
1
2
1
2
.
t
0
0
1
T
a
b
l
e
1
.
C
o
n
t
.
Causal Effects: BMI and Ischemic Heart Disease
PLoS Medicine | www.plosmedicine.org 3 May 2012 | Volume 9 | Issue 5 | e1001212Copenhagen General Population Study. This general
population study was initiated in 2003 with ongoing enrolment
[26–29]. IHD endpoints have been collected from 1976 to May
2009. Individuals were selected on the basis of the national Danish
Civil Registration System to reflect the adult Danish population
aged 20–100 y. Data were obtained from a questionnaire, a
physical examination, blood samples, and from DNA. At the time
of genotyping 59,883 participants had been included; of these,
5,270 were used as controls in the CIHDS (see below), leaving
54,613 for analyses in the CGPS.
Copenhagen City Heart Study. This prospective general
population study was initiated in 1976–1978 with follow-up
examinations in 1981–1983, 1991–1994, and 2001–2003 [26].
Participants were recruited and examined exactly as in the CGPS.
DNA was available on 10,474 participants attending the 1991–
1994 and/or 2001–2003 examinations.
Copenhagen Ischemic Heart Disease Study. This case-
control study comprises 5,270 patients from the greater Copenhagen
area referred for coronary angiography to Copenhagen University
Hospital duringtheperiod 1991–2009 and 5,270 unmatchedcontrols
without IHD randomly sampled from the CGPS. Beside a diagnosis
of IHD as described below, these patients also had stenosis/
atherosclerosis on coronary angiography and/or a positive exercise
electrocardiography test.
Ischemic Heart Disease
In all three studies, information on diagnosis of IHD (World
Health Organization International Classification of Diseases:
ICD8 410–414; ICD10 I20–I25) was collected and verified from
existing data from 1976 until May 2009 by reviewing all hospital
admissions and diagnoses entered in the national Danish Patient
Registry and all causes of death entered in the national Danish
Causes of Death Registry. Even though some individuals entered
into our studies after 1976, we have complete information on all
participants on any hospitalisation or death from IHD from 1976
through 2009 through these registries. IHD was angina pectoris
and/or myocardial infarction (ICD8 410; ICD10 I21–I22), based
on characteristic chest pain, electrocardiographic changes, and/or
elevated cardiac enzymes. Follow-up was 100% complete, that is,
no individual was lost to follow-up in any of the studies.
Genotyping
Genotyping was conducted blind to phenotypic data. In the
absence of genomewide data, the ABI PRISM 7900HT Sequence
Detection system (Applied Biosystems Inc.) was used to genotype
the BMI instrument loci: FTO(rs9939609), MC4R(rs17782313), and
TMEM18(rs6548238) using TaqMan assays. Polymorphisms were
selected as those with the largest known common effect sizes for
association with BMI in European populations [14,30]. Genotyping
wasverified byDNAsequencing,qualitycontrolgenotypingre-runs
wereperformed twice, and 99.96% of all available participants were
genotyped. To act as an aggregate instrument for BMI, a simple
score of 0–6 was constructed as the sum of the number of higher
BMI-associated alleles across the three genotypes in each study. To
check results from this simplest form of allelic score, weighted allele
score was also calculated. This score was generated by taking the
weighted sum of the number of BMI ‘‘elevating’’ alleles at each
locus scaled per standard deviation increase in BMI. Independent
gene variant/BMI effect estimates used were taken from the largest
available GWAS for BMI to date [14].
Body Mass Index
BMI was calculated as measured weight (kg) divided by
measured height squared (m
2). To exclude influence of age and
sex on our results, BMI was standardised into age- and sex-
adjusted Z-scores within each study separately (Table S1). One Z-
score corresponds to a BMI standard deviation of 4 kg/m
2; thus,
for easy interpretation of data, results in Z-scores were converted
Table 2. Distribution of FTO, MC4R, and TMEM18 genotypes in the CGPS, CCHS, and CIHDS.
Genotype or Allele Score 0 1 2 3 4 5 6
Genotype
CPGS
FTO(rs9939609), n (%) 17,846 (35.2) 24,595 (48.5) 8,307 (16.4)
MC4R(rs17782313), n (%) 28,797 (56.7) 18,862 (37.2) 3,092 (6.1)
TMEM18(rs6548238), n (%) 1,517 (2.9) 15,036 (28.4) 36,435 (68.9)
CCHS
FTO(rs9939609), n (%) 3,744 (35.8) 4,981 (47.6) 1,748 (16.7)
MC4R(rs17782313), n (%) 5,998 (57.3) 3,841 (36.7) 635 (6.1)
TMEM18(rs6548238), n (%) 316 (3.0) 2,975 (28.4) 7,180 (68.6)
CIHDS
FTO(rs9939609), n (%) 3,613 (34.3) 5,159 (49.0) 1,768 (16.8)
MC4R(rs17782313), n (%) 5,913 (56.1) 3,930 (37.3) 697 (6.6)
TMEM18(rs6548238), n (%) 279 (2.7) 2,955 (28.0) 7,306 (69.3)
Allele score
CPGS, n (%) 58 (0.6) 738 (7.1) 2,782 (26.6) 3,768 (36.0) 2,386 (22.8) 658 (6.3) 80 (0.8)
CCHS, n (%) 294 (0.6) 3,452 (6.8) 13,203 (26.0) 18,578 (36.6) 11,556 (22.8) 3,283 (6.5) 349 (0.7)
CIHDS, n (%) 55 (0.5) 682 (6.5) 2,672 (25.4) 3,831 (36.4) 2,506 (23.8) 721 (6.8) 73 (0.7)
All SNPs adhere to Hardy-Weinberg Equilibrium (p.0.2). FTO(rs9939609) genotypes, 0 (TT), 1 (AT), 2 (AA); MC4R(rs17782313) genotypes 0 (TT), 1 (CT), 2 (CC);
TMEM18(rs6548238) genotypes 0 (TT), 1 (CT), 2 (CC). Allele score constructed from the following genotypes: FTO(rs9939609), 0 (TT), 1 (AT), 2 (AA); MC4R(rs17782313), 0
(TT), 1 (CT), 2 (CC); TMEM18(rs6548238), 0 (TT), 1 (CT), 2 (CC).
doi:10.1371/journal.pmed.1001212.t002
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2. Participants with BMI greater than
50 kg/m
2 were excluded from observational and instrumental
variable estimates. BMI measurements were not available for the
patients in the CIHDS, hence observational estimates of the IHD-
BMI association are not given for this study.
Other Covariates
Smoking was categorized from self-reported data as ever versus
never smoked, alcohol consumption was categorized as ,14/21
or $14/21 units per week for women/men (1 unit=12 g),
education as schooling for ,10, $10 to ,13, and $13 y, and
annual income as ,100,000DKK, 100,000DKK–400,000DKK,
400,000DKK–600,000DKK, and .600,000DKK. Use of statins
was recorded at examination. Measured systolic and diastolic
blood pressure was recorded as described previously [31] and
adjusted for antihypertensive medication by adding a constant
value of 10 mmHg and systolic blood pressure and 5 mmHg for
diastolic blood pressure [32]. Plasma levels of triglycerides, glucose,
high-density lipoprotein cholesterol, and low-density lipoprotein
cholesterol were measured using standard hospital assays. Time
Figure 1. ORs and 95% CIs for IHD by BMI categories in the CGPS and the CCHS.
doi:10.1371/journal.pmed.1001212.g001
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PLoS Medicine | www.plosmedicine.org 5 May 2012 | Volume 9 | Issue 5 | e1001212between IHD event and BMI measurement (‘‘event time’’) was
assessed as a confounding factor in supplementary analyses.
Statistical Analysis
All analyses were performed in Stata version 11 (StataCorp).
For genotypes a deviation from Hardy-Weinberg equilibrium was
investigated using a Pearson chi-squared test. Observational
estimates of odds ratios (ORs) of IHD per unit increase in
standardised BMI, allele score, and potential confounders were
estimated using logistic regression. Estimates of the association of
standardised BMI with allele score and potential confounders were
performed using linear regression. Associations of potential
confounders by genotype and allele score were estimated using
logistic regression, linear regression, and Pearson’s chi-squared
test.
Instrumental variable estimates of causal ORs were derived
using the Wald-type estimator [33], which involves taking the ratio
of the IHD-allele score log OR to the standardised BMI-allele
score coefficient and then exponentiating to express as an OR.
The standardised BMI-allele score coefficient comes from all
individuals from the general population with BMI available, that
is, all participants other than those in the CIHDS. Standard errors
of Wald-type instrumental variable log ORs were derived using
the delta method [34]. Instrumental variable estimates derived
from this approach (which is the most efficient use of data) were
verified by comparing them to analyses in the CGPS and CCHS
using a logistic structural mean model fitted using the three
genotypes as separate, weighted, instruments [35]; these models
were fitted in the CGPS and CCHS as they require observations of
genotypes, BMI, and IHD status for each individual. In these
models the joint validity of the multiple instruments was
investigated using Hansen’s over-identification test [36]. If such
a test is rejected it indicates one or more of the instruments may
not be valid instruments. As a comparison to using a non-weighted
allele score, analyses were also undertaken using a weighted allele
score.
In a case-control study like the CIHDS, the allele score-IHD
association is valid as in cohort studies like the CGPS and the
CCHS because it is not affected by IHD status and represents
lifecourse BMI-associated IHD risk. BMI may be affected by IHD,
because some patients loose weight after an IHD diagnosis.
Therefore, the allele score-BMI association entering into the
instrumental variable analyses is best derived from people in the
general population as done in the present study. The advantage of
including the CIHDS together with the CGPS and the CCHS is
that it adds considerable statistical power to the combined
analyses, as done by ourselves in previous studies [27–29].
Importantly, however, when the CGPS and the CCHS are
combined and CIHDS is excluded, the results are similar.
Meta-analysis pooled estimates were obtained using the random
effects meta-analysis model implemented in the user-written Stata
command ‘‘metan’’ [37]. In each meta-analysis, between-study
heterogeneity was assessed using the I
2 statistic and the Cochran
heterogeneity Q test. Meta-analysis of ORs was performed on the
log scale. Analysing the three studies as a single dataset was
Figure 2. Meta-analysis forest plots of observational and instrumental variable causal estimates using allele score of the
relationship between IHD and BMI. The ORs are for a 4 kg/m
2 increase in BMI.
doi:10.1371/journal.pmed.1001212.g002
Table 3. Observational ORs for IHD per 4 kg/m
2 increase in
BMI.
Study OR (95% CI) OR (95% CI)
a OR (95% CI)
b
CGPS 1.23 (1.19–1.28) 1.21 (1.17–1.24) 1.22 (1.18–1.26)
CCHS 1.31 (1.23–1.39) 1.31 (1.24–1.38) 1.22 (1.15–1.29)
Pooled 1.27 (1.19–1.34) 1.25 (1.16–1.36) 1.22 (1.18–1.26)
Pooled estimates from fixed effects meta-analysis.
aAdjusted for sex, smoking status, drinking status, years of education, income
level.
bAdjusted for sex, smoking status, drinking status, years of education, income
level, and event time.
doi:10.1371/journal.pmed.1001212.t003
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those of the meta-analyses throughout.
Results
The numbers of IHD patients were 3,780 of 54,613 participants
in the CGPS (79% prevalent and 21% incident), 2,006 of 10,474
participants in the CCHS (22% prevalent and 78% incident), and
5,270 of 10,540 participants in the CIHDS (100% prevalent).
Baseline characteristics of participants in the three studies are
shown in Table 1. Genotypes scored for FTO(rs9939609),
MC4R(rs17782313), and TMEM18(rs6548238) were in Hardy-
Weinberg equilibrium in the three studies and the distribution of
the allele score was approximately normal (Table 2).
BMI and IHD Risk: Observational Estimate
In the general population, for one standard deviation (4 kg/m
2)
increase in BMI, the observational ORs for IHD were 1.23 (95%
CI 1.19–1.28) for the CGPS and 1.31 (95% CI 1.23–1.39) for the
CCHS (Figure 1). The meta-analysis pooled OR was 1.26 (95%
CI 1.19–1.34), and there was some evidence of between-study
heterogeneity (I
2=63; p=0.10), but this was incorporated in the
random effects model (Figure 2). These observational associations
were unaffected on adjustment for the potential confounders of
sex, smoking status, drinking status, years of education, and
income level and attenuated on additional adjustment for event
time (Table 3). If ever smokers were separated into current and
former smokers and drinkers into moderate and heavy drinkers,
observational associations were unaffected. Where available
(CPGS), analysis including adjustment for statin use showed
evidence for an attenuation in estimates of the relationship
between BMI and IHD risk (adjusted OR for IHD per 4 kg/m
2
increase in BMI 1.12 [1.08–1.16]).
Genotype and Allele Score Associations with BMI
Pooled across the three studies, each additional adiposity-related
allele from the allele score was associated with a 0.28 kg/m
2 (95%
CI 0.22–0.34) increase in BMI (Figure 3), corresponding to a
1.68 kg/m
2 (95% CI 1.31–2.06) BMI increase for a comparison of
the minimum (0) to maximum (6) carriage of adiposity increasing
alleles. These results were similar across cases and controls in the
three separate studies.
Associations with Confounding Factors
In an analysis such as this one, it is important to examine
whether potential confounding factors could be part of the
explanation behind an observational BMI-IHD association, or
behind a causal BMI-IHD association estimated using allele score
in instrumental variable analysis. For a potential confounder to be
part of the explanation behind an association, the factor in
question needs to associate both with the exposure and the
outcome.
We therefore examined both the association between potentially
confounding factors (sex, age, smoking status, drinking status,
education, income, and event time) and our primary exposure
(BMI), our primary outcome (IHD), and our instrumental
variables (genotypes and allele score). For both our primary
outcome and exposure, there was strong evidence for association
between both BMI, IHD, and drinking, education, income, and
event time (Tables S2 and S3). In contrast, genotypes at
FTO(rs9939609), MC4R(rs17782313), and TMEM18(rs6548238)
and the allele score demonstrated no reliable evidence of
association with potential confounders (Table 4).
In aggregate, these data suggest that several factors likely could
confound the observational BMI-IHD association. In contrast, it is
unlikely that these same factors should confound the instrumental
Figure 3. Meta-analysis forest plots of the relationships between FTO rs9939609, MC4R rs17782313, and TMEM18 rs6548238 allele
score and BMI. Analyses are stratified by IHD status.
doi:10.1371/journal.pmed.1001212.g003
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these factors were not associated with genotype or allele score.
Allele Score and IHD Risk
In the CGPS the OR for IHD per risk allele, that is per
0.28 kg/m
2 increase, was 1.02 (95% CI 0.98–1.05), in the CCHS
1.05 (95% CI 1.01–1.11), and in the CIHDS 1.03 (95% CI 1.00–
1.07). The meta-analysed OR per risk allele was 1.03 (95% CI
1.01–1.05), with no evidence of between-study heterogeneity
(I
2=0,p=0.43) (Figure 4). This finding corresponds to an OR for
IHD of 1.20 (95% CI 1.05–1.36) for a maximum allele score
comparison of 0–6 adiposity increasing alleles corresponding to a
1.68 kg/m
2 increase. The increasing trend in BMI with allele
score, distribution of allele score, and the relative differences in
BMI by IHD status can be seen simultaneously in Figure 5. The
relatively high value of BMI at 0 allele score is likely due to the
play of chance, given that there are relatively few individuals with
this allele score. The absolute BMI values are higher in the CGPS
because participants were recruited approximately 15 y after the
CCHS, during which time Danish people on average become
Table 4. Associations of potential confounders with genotypes in the three studies.
Potential Confounders with Genotypes
or Allele Score OR (95% CI) on Logistic Regression
a or on Linear Regression
b
CGPS CCHS CIHDS
Sex
a
FTO (rs9939609) 1.02 (0.99–1.04) 0.95 (0.90–1.00) 1.01 (0.95–1.06)
MC4R (rs17782313) 0.99 (0.96–1.01) 0.95 (0.89–1.01) 1.06 (1.00–1.13)
TMEM18 (rs6548238) 0.99 (0.96–1.03) 0.95 (0.89–1.03) 1.02 (0.94–1.09)
Allele score 1.00 (0.98–1.02) 0.95 (0.92–0.99) 1.03 (0.99–1.07)
Ever smoked
a
FTO (rs9939609) 1.02 (1.00–1.05) 0.95 (0.90–1.01) 1.03 (0.97–1.09)
MC4R (rs17782313) 1.01 (0.98–1.04) 1.02 (0.95–1.08) 0.98 (0.91–1.04)
TMEM18 (rs6548238) 1.03 (1.00–1.06) 1.05 (0.97–1.12) 1.00 (0.92–1.08)
Allele score 1.02 (1.00–1.04) 1.00 (0.96–1.03) 1.00 (0.96–1.04)
Drinking
b
FTO (rs9939609) 0.97 (0.95–1.00) 0.93 (0.88–0.99) 1.00 (0.94–1.06)
MC4R (rs17782313) 0.99 (0.96–1.03) 0.95 (0.89–1.01) 0.99 (0.92–1.06)
TMEM18 (rs6548238) 0.98 (0.95–1.02) 1.03 (0.96–1.11) 1.01 (0.93–1.10)
Allele score 0.98 (0.97–1.00) 0.96 (0.93–1.00) 1.00 (0.96–1.04)
Age (y)
b
FTO (rs9939609) 20.02 (20.19 to 0.15) 0.06 (20.38 to 0.50) 0.09 (20.26 to 0.44)
MC4R (rs17782313) 0.10 (20.10 to 0.30) 0.15 (20.36 to 0.65) 0.25 (20.14 to 0.63)
TMEM18 (rs6548238) 20.05 (20.27 to 0.16) 0.69 (0.11–1.27) 0.04 (20.41 to 0.50)
Allele score 0.02 (20.10 to 0.13) 0.24 (20.05 to 0.53) 0.13 (20.09 to 0.36)
Event time
b
FTO (rs9939609) 0.00 (20.03 to 0.03) 0.01 (20.14 to 0.15) 0.02 (20.04 to 0.08)
MC4R (rs17782313) 20.01 (20.04 to 0.02) 0.05 (20.12 to 0.21) 20.03 (20.09 to 0.04)
TMEM18 (rs6548238) 0.02 (20.02 to 0.05) 20.16 (20.35 to 0.03) 0.05 (20.03 to 0.12)
Allele score 0.00 (20.02 to 0.02) 20.02 (20.12 to 0.08) 0.01 (20.03 to 0.05)
Education
a
FTO (rs9939609) 0.99 (0.96–1.02) 0.92 (0.85–1.01) 0.95 (0.86–1.04)
MC4R (rs17782313) 1.00 (0.97–1.04) 0.93 (0.84–1.03) 0.94 (0.84–1.05)
TMEM18 (rs6548238) 1.00 (0.96–1.04) 0.95 (0.85–1.06) 0.91 (0.80–1.04)
Allele score 0.99 (0.97–1.02) 0.93 (0.88–0.99) 0.94 (0.88–1.00)
Income
a
FTO (rs9939609) 0.99 (0.96–1.03) 0.98 (0.85–1.13) 0.99 (0.93–1.06)
MC4R (rs17782313) 0.98 (0.95–1.02) 0.96 (0.81–1.13) 1.03 (0.95–1.11)
TMEM18 (rs6548238) 0.94 (0.91–0.98) 0.90 (0.75–1.08) 1.00 (0.91–1.10)
Allele score 0.98 (0.96–1.00) 0.96 (0.87–1.05) 1.01 (0.96–1.05)
Drinking represented by ,14/21; $14/21 units per week for women/men at the time of examination. Education represented by less or more than 13 y schooling.
Income represented by annual income less or more than 400,000DKK. Event time is absolute difference between age at IHD event and age at measurement of BMI (y).
aLogistic regression.
bLinear regression.
doi:10.1371/journal.pmed.1001212.t004
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adjustment for statin use showed no strong evidence of attenua-
tion, (adjusted OR for IHD per risk allele 1.01 [95% CI 0.98–
1.05]).
BMI and IHD Risk: Instrumental Variable Causal Estimate
Using Allele Score
An instrumental variable analysis using allele score examines the
causal effect of a lifecourse change in BMI on the risk of IHD. The
instrumental variable estimate of the causal relationship between a
4 kg/m
2 increase in BMI and IHD showed an OR of 1.31 (95%
CI 0.76–2.26) in the CGPS, 2.11 (95% CI 1.05–4.24) in the
CCHS, and 1.46 (95% CI 0.96–2.24) in the CIHDS. The meta-
analysed causal OR was 1.52 (95% CI 1.12–2.05), with no
evidence of between-study heterogeneity (I
2=0, p=0.56)
(Figure 2). These results were similar using a weighted allele score
(Figure S1), rather than the non-weighted model used above.
There was no strong evidence of a difference between instrumental
variable and observational ORs (p=0.25 for difference). Where
available (CPGS), analysis including adjustment for statin use
showed that, in contrast to observational analysis, there was no
evidence for an attenuation of the estimate (adjusted OR for IHD
per 4 kg/m
2 increase in BMI 1.28 [0.69–2.37]).
Instrumental variable estimates based on the use of individual
SNPs gave broadly similar results, but with reduced statistical
power (Figure S2). Also instrumental variable estimates from a
logistic structural mean model gave similar estimated causal ORs
(Figure S3). In these models there was no evidence against the joint
validity of using these SNPs as multiple instruments (CGPS,
p=0.97; CCHS, p=0.91).
As the relationships between BMI and health outcomes can be
attenuated with age, we performed subgroup analyses in
individuals above and below age 60 y. There was evidence of
smaller observational ORs for IHD in those above versus below
60 y (p=0.02 for difference). This finding was reflected in
evidence for interaction between age group and BMI when
included in the logistic regression of IHD on BMI and age group
(p=0.01 [CGPS], p,0.001 [CCHS] for interaction). Instrumen-
tal variable estimates gave no evidence of difference by age
(Figure 6).
BMI and IHD Risk: Observational Versus Instrumental
Variable Causal Estimate Using Allele Score
In summary, in observational analyses for every 4 kg/m
2
increase in BMI, the OR for IHD was 1.26 (95% CI 1.19–1.34),
corresponding to a 26% increased IHD risk (Figure 2). For
comparison, in instrumental variable analysis using the allele score
the causal IHD ORs for a 4 kg/m
2 increase in BMI was 1.52 (95%
CI 1.12–2.05), corresponding to a 52% increased IHD risk.
Discussion
In two large studies of the general population, observational
estimates suggested a 26% increase in risk of IHD for every 4 kg/
m
2 increase in BMI. A unit change of an allelic score combining
genotypes from three established genetic associates of BMI was
associated with a 0.28 kg/m
2 change in BMI, a change neither
correlated with classic confounding features nor affected by
reverse causation. Using this as an instrument for lifecourse BMI
difference in 75,627 Danish individuals from the same general
population studies and a further case-control series, instrumental
variable analysis was employed to re-estimate the causal
relationship between BMI and IHD risk. In doing this, estimates
suggest that the same increase in BMI is causally related to an
increased risk of IHD consistent with observational estimates, if
not greater. Whilst features such as statin use appear to impact
observational estimates, those based on genetic instruments for
BMI appear consistent across sub-analyses. Importantly, we not
only qualify the likely causal role of BMI (rather than just an
observational associate), we are able to quantify this effect. It
should be mentioned that the causal relationship between
increased BMI and increased risk of IHD may be realised
through intermediate factors like hypertension, dyslipidemia, and
type 2 diabetes.
The design of this study and the use of genetic variation as a
proxy marker for elevated BMI lead to additional discussion
Figure 4. Meta-analysis forest plots of the relationships between FTO rs9939609, MC4R rs17782313, and TMEM18 rs6548238 allele
score and IHD.
doi:10.1371/journal.pmed.1001212.g004
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for forms of study bias to be effectively accounted for. For
example, observational relationships between BMI and IHD risk
tend to increase with time from BMI measurement largely as a
result of tracking and the natural progression of BMI with age [2].
In contrast to this, where IHD events are recorded before BMI,
reverse causation can reduce the strength of relationships between
BMI and IHD, though illness-induced weight loss adds further
complication to the assessment of relationships between body
weight and mortality [11]. Genetic instruments are not related to
this time difference and the use of these as proxy markers for BMI
removes the limitations that can be brought about by the existence
of these biases. Use of genetic variation as a proxy measure for
lifecourse BMI change also helps to avoid regression dilution bias,
or the artefactual underestimation of epidemiological associations
owing to a failure of baseline measurements to reliably collect the
‘‘usual’’ levels of an exposure [38]. Existing studies have made
efforts to account forthisand other‘‘confounding at baseline’’ issues
[2,3,6]; however, these effects are difficult to quantify. Owing to the
consistent nature of genotype effects through adult life [14,39], this
type of loss in measurement precision is minimised. Indeed, as a
result of Mendelian randomisation-derived estimates modelling
lifecourse differences in BMI, we would anticipate effect estimates
that can be larger than those from more conventional observational
approaches, as seen in this case.
Despite these benefits, there are a number of potential
limitations in Mendelian randomisation studies like the present
one [13,40,41]. However, the complicating effect of population
stratification in Mendelian randomisation studies is likely to have
been avoided through the use of an ethnically homogenous white
population in the present study. Also, pleiotropy and the
potentially confounding effects of linkage disequilibrium are likely
avoided owing to the use of multiple genetic polymorphisms, each
associated with increased BMI and each acting on BMI
Figure 5. Mean BMI and 95% CIs by allele score and IHD status and distribution of allele score in the CGPS and CCHS. Left y-axis and
dot with 95% CI depict BMI values as a function of allele score. Right y-axis and histogram depict frequency in percent of the different allele scores.
doi:10.1371/journal.pmed.1001212.g005
Causal Effects: BMI and Ischemic Heart Disease
PLoS Medicine | www.plosmedicine.org 10 May 2012 | Volume 9 | Issue 5 | e1001212independently and via different pathways. Nevertheless, canalisa-
tion cannot be completely excluded as a limitation of the present
study; however, as canalisation theoretically acts to buffer the
effect of genetic deviations, it can obscure associations between
genes and IHD, but it is unlikely to explain away the results in this
study. Also, although the analyses provide insight into the likely
causal effect of lifecourse elevations in BMI, we are not well placed
to comment on the impact of acute changes. Lastly, there are
known limitations to the use of BMI as a marker for adiposity or
other possible anthropometrically related aetiological contribu-
tions to IHD risk, and using alternative measures may prove more
informative [42]. Nevertheless, these potential limitations to BMI
cannot explain the results in this study.
In the context of available evidence concerning the causal role of
BMI as an intermediate risk factor for IHD, we can speculate that
the explanation for the causal association is straightforward:
increased BMI contributes causally to well-known cardiovascular
risk factors including hypertension, dyslipidemia, and type 2
diabetes, factors that may then go on to cause the observed
increased risk of IHD. Similar evidence supporting the role of
elevated BMIinthegenerationof a commonrisk profile is emerging
[23,24,31,43,44] and in combination with the agreement of these
findings with those of observational studies, an important role for
BMI is evident from work using other techniques to avoid the
problems of confounding and reverse causation [22,45,46].
In conclusion, for every 4 kg/m
2 increase in BMI, observa-
tional estimates suggested a 26% increase in IHD risk with
instrumental variable analysis suggesting a causal 52% increase
in IHD risk. These data add novel evidence to support a causal
link between increased BMI and increased IHD risk, while the
mechanism of this effect is likely to be operating through
intermediate factors. In the context of recent, high impact,
observational findings, this work has important policy implica-
tions for public health given the continuous nature of the BMI-
IHD association, the modifiable nature of BMI, and the likely
benefits of reducing BMI even by moderate levels. Finally, this
analysis demonstrates the value of observational studies and their
ability to provide essentially unbiased results because of inclusion
of genetic data avoiding confounding, reverse causation, and
bias.
Supporting Information
Figure S1 Meta-analysis forest plots of observational and
instrumental variable estimates using a weighted allele score of
the relationship between IHD and standardised BMI.
(TIF)
Figure S2 Meta-analysis forest plots of instrumental variable
causal estimates of the relationship between IHD and BMI
stratified by genotype. FTO rs9939609, MC4R rs17782313, and
TMEM18 rs6548238.
(TIF)
Figure S3 Meta-analysis of logistic structural mean model causal
OR estimates of IHD risk per 4 kg/m
2 increase in BMI in the
CGPS and CCHS. Logistic structural mean models fitted using
FTO, MC4R, and TMEM18 genotypes as multiple instruments,
with each genotype under an additive model. The first stage
association model was fitted with an intercept and the main effects
of standardised BMI and each of the three genotypes.
(TIF)
Figure 6. Meta-analysis forest plots of observational and instrumental variable estimates of the relationship between IHD and BMI
stratified by age group.
doi:10.1371/journal.pmed.1001212.g006
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Background. Ischemic heart disease (IHD; also known as
coronary heart disease) is the leading cause of death among
adults in developed countries. In the US alone, IHD kills
nearly half a million people every year. With age, fatty
deposits (atherosclerotic plaques) build up in the walls of the
coronary arteries, the blood vessels that supply the heart
with oxygen and nutrients. The resultant reduction in the
heart’s blood supply causes shortness of breath, angina
(chest pains that are usually relieved by rest), and potentially
fatal heart attacks (myocardial infarctions). Risk factors for
IHD include smoking, high blood pressure (hypertension),
abnormal amounts of cholesterol and other fat in the blood
(dyslipidemia), type 2 diabetes, and being overweight or
obese (having excess body fat). Treatments for IHD include
lifestyle changes (for example, losing weight) and medica-
tions that lower blood pressure and blood cholesterol levels.
The narrowed arteries can also be widened using a device
called a stent or surgically bypassed.
Why Was This Study Done? Prospective observational
studies have shown an association between a high body
mass index (BMI, a measure of body fat that is calculated by
dividing a person’s weight in kilograms by their height in
meters squared; a BMI greater than 30 kg/m
2 indicates
obesity) and an increased risk of IHD. Observational studies,
which ask whether people who are exposed to a suspected
risk factor develop a specific disease more often than people
who are not exposed to the risk factor, cannot prove,
however, that changes in BMI/adiposity cause IHD. Obese
individuals may share other characteristics that cause both
IHD and obesity (confounding) or, rather than obesity
causing IHD, IHD may cause obesity (reverse causation).
Here, the researchers use ‘‘Mendelian randomization’’ to
examine whether elevations in BMI across the lifecourse have
a causal impact on IHD risk. Three common genetic
variants—FTO(rs9939609), MC4R(rs17782313), and
TMEM18(rs6548238)—which have the largest single genetic
variant associations with BMI were used in this study. Given
that gene variants are inherited essentially randomly with
respect to conventional confounding factors and are not
subject reverse causation, use of these as instruments (or
proxy measures) for variation in BMI as a risk factor (as
opposed to measuring BMI directly) allows researchers to
comment on whether obesity is causally involved in IHD.
What Did the Researchers Do and Find? The researchers
analyzed data from two population-based studies in which
adults were physically examined and answered a lifestyle
questionnaire before being followed to see how many
developed IDH. They also analyzed data from a case-control
study on IDH (in a case-control study, people with a disease
are matched with similar people without the disease and the
occurrence of risk factors in the patients and controls is
compared). Overall, the researchers measured the BMI of
75,627 white individuals, among whom 11,056 already had
IDH or developed it, and determined which of the BMI-
increasing genetic variants each participant carried. On the
basis of the observational data, every 4 kg/m
2 increase in
BMI increased the odds of IDH by 26% (an odds ratio of 1.26).
Using a score derived from the combination of the three
genetic variants, the researchers confirmed an association
between each BMI increasing allele and both BMI (as
expected) and IHD (0.28 kg/m
2 and an odds ratio for IHD
of 1.03, respectively). On average, compared to people
carrying no BMI-increasing gene variants, people carrying six
BMI-increasing gene variants had a 1.68 kg/m
2 increase in
BMI and an 18% increase in IHD risk. To extend this and to
essentially reassess the original, observational, relationship
between BMI and IHD risk, an ‘‘instrumental variable
analysis’’ was used to examine the causal effect of a lifetime
change in BMI on the risk of IDH. In this, it was found that for
every 4 kg/m
2 increase in BMI increased the odds of IDH by
52%.
What Do These Findings Mean? These findings support a
causal link between increased BMI and IDH risk, although it
may be that BMI affects IDH through intermediate factors
such as hypertension, dyslipidemia, and diabetes. The
findings also show that observational studies into the impact
of elevated BMI on IHD risk were consistent with this, but
also that the inclusion of genetic data increases the value of
observational studies by making it possible to avoid issues
such as confounding and reverse causation. Finally, these
findings and those of recent, observational studies have
important implications for public-health policy because they
show that the association between BMI (which is modifiable
by lifestyle changes) and IHD is continuous. That is, any
increase in BMI increases the risk of IHD; there is no threshold
below which a BMI increase has no effect on IDH risk. Thus,
public-health policies that aim to reduce BMI by even
moderate levels could substantially reduce the occurrence of
IDH in populations.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001212.
N The American Heart Association provides information
about IHD and tips on keeping the heart healthy, including
weight management; it also provides personal stories
about IHD
N The UK National Health Service Choices website provides
information about IHD, including information on
prevention and personal stories about IHD
N Information is available from the British Heart Foundation
on heart disease and keeping the heart healthy
N The US National Heart Lung and Blood Institute also
provides information on IHD (in English and Spanish)
N MedlinePlus provides links to many other sources of
information on IHD (in English and Spanish)
N Wikipedia has a page on Mendelian randomization (note:
Wikipedia is a free online encyclopedia that anyone can
edit; available in several languages)
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